… ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of … in Tübingen, Investigator in the ILLUMINATE trial. “ProQR’s RNA therapy for the p.Cys998X mutation showed the … Aniz Girach, Ophthalmologist and Chief Medical Officer of ProQR. “With the ongoing trials in LCA10 and Ushers syndrome …
… ProQR Announces Presentations and Investor & Analyst Event at … LEIDEN, the Netherlands, Oct. 24, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … Questionnaire-Revised Respiratory Symptom Score, or CFQ-R RSS) compared to placebo. A supportive trend was observed …
… On a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day LEIDEN, the Netherlands, Feb. … said Daniel A. de Boer, Chief Executive Officer of ProQR. “Together with our partners at the Leiden Bio Science … Sariette Witte Investor Relations T: +1 213 261 8891 ir@proqr.com …
… ProQR Announces Results for the Fourth Quarter and Full Year … said Daniel A. de Boer, Chief Executive Officer of ProQR. “QR-110, our second development program targeting … for QR-313 is expected to start in 2018. ProQR’s inaugural R&D day provides key updates on drug pipeline: On March 14 th …
… ProQR Announces Results for the Fourth Quarter and Full Year … of 2017 and Business Update QR-110 for LCA 10 In April, ProQR’s QR-110 for Leber’s congenital amaurosis 10 (LCA 10) … Questionnaire-Revised Respiratory Symptom Score, or CFQ-R RSS) compared to placebo. A supportive trend was observed …
Platform demonstrates robust in vivo editing capabilities reporting up to 70% editing of ACTB in the liver of non-human primates (NHPs) and miceFunctional effect demonstrated in mice in vivo via modulation of ANGPLT3 protein properties leading to favora
Top-line results expected H1 2022
Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan.
